SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is currently trending as investors debate the company's long-term commercial viability versus its ongoing manufacturing challenges at the Fab2 facility. While some community members are highlighting the potential of the Meta-Bounds partnership and high-energy-density silicon-anode technology, others remain focused on the stock hitting all-time lows and express frustration over the lack of major purchase orders.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is currently a focal point for investors due to heavy short interest, widespread speculation regarding a potential privatization or buyout deal, and an aggressive international expansion strategy. Community discussion remains polarized, with many retail traders actively accumulating shares and advocating for a short squeeze while others express frustration over the delayed CEO search and inconsistent store performance.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing intense selling pressure as a major analyst firm highlighted significant downside risk due to deteriorating financial metrics and weakening EV demand. Community sentiment is deeply divided, with some investors panic-selling into the decline, while others continue to debate the stock's future value based on the potential impact of Elon Musks focus shifting toward private ventures like SpaceX.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is currently capturing community attention as traders analyze the interplay between anticipated U.S. regulatory clarity, such as the potential passing of the Clarity Act, and ongoing institutional infrastructure developments like Ripple's integration with SWIFT. While some investors express frustration over price stagnation and ongoing legal uncertainty, others remain bullish on the long-term utility of the Ripple ecosystem and the potential for a breakthrough driven by wider institutional adoption.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is trending due to the upcoming April 10 PDUFA date for RP1, with the community deeply divided between bullish investors betting on FDA approval following the recent BLA resubmission and bearish traders anticipating a second Complete Response Letter (CRL) based on historical efficacy concerns. Discussions are heavily focused on the high-stakes binary nature of this regulatory event, with many participants debating the potential for a share price collapse or a short squeeze given the significant short interest and volatile options flow.

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Target is gaining momentum as investors react to a strategic leadership shakeup and a refocus on store staffing, while community sentiment remains divided between those betting on a value-driven turnaround and critics concerned about ongoing political headwinds and consumer spending shifts.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is currently experiencing intense market volatility, driven by a blend of speculative short-squeeze activity and skepticism regarding its fundamental financial health, including high debt levels and negative free cash flow. While the stock has seen aggressive price swings and heavy institutional interest, the community remains sharply divided, with bulls pointing to potential recovery catalysts and bears warning that current price levels are disconnected from the company's long-term operational challenges.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense & Security Solutions is trending following a significant capital raise through a public stock offering, an event that has triggered debate among investors regarding short-term dilution versus long-term growth capacity. The stock remains a focal point for the defense community due to robust analyst upgrades, strong revenue growth expectations tied to Valkyrie drone production, and broader tailwinds from a substantial increase in projected U.S. defense spending.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

United Parcel Service (UPS) is trending as investors weigh aggressive turnaround efforts, including a massive restructuring plan to cut 30,000 jobs and reduce Amazon shipping volumes, against concerns about near-term margin pressure and operational headwinds. While the community is actively debating the stock's long-term value and turnaround potential, the conversation is split between those viewing the company's cost-cutting as a necessary strategic reset and skeptics worried about the impact of a softening shipping environment.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is seeing a surge in investor attention as the community anticipates major contract announcements linked to its role as a key reliability gatekeeper for AI infrastructure. Traders are closely monitoring the stock's proximity to all-time highs and watching for potential updates on follow-on orders following recent positive guidance and increased interest from hyperscale data center partners.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting

Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting Actinium...

Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting

Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting PR Newswire NEWYORK...

Are Medical Stocks Lagging  Actinium Pharmaceuticals (ATNM) This Year?

Here is how Actinium Pharmaceuticals (ATNM) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.

<ul class="summary-bullets"><li>The company’s latest research shows ATNM-400 achieving substantial tumor-growth suppression.</li><li>The therapy targets a validated antigen overexpressed in breast cancer and other solid tumors, such as Prostate Cancer and Non-Small Cell Lung Cancer.</li><li>Researchers observed that ATNM-400 induced irreversible DNA damage.</li></ul>Actinium Pharmaceuticals, Inc. (ATNM) stock was in the spotlight on Friday after the company announced promising new preclinical findings for its novel radiotherapy, ATNM-400, at the 2025 San Antonio Breast Cancer Symposium (SABCS).&nbsp;The Actinium-225 (Ac-225) antibody radioconjugate demonstrated strong anti-tumor activity across multiple breast cancer models, including hormone receptor–positive (HR+), triple-negative (TNBC), and treatment-resistant tumors.<h2 class="st-heading-2">ATNM-400’s Broad Potential</h2>The company’s latest research shows ATNM-400 achieving substantial tumor-growth suppression with minimal side effects in preclinical studies.&nbsp;The therapy targets a validated antigen overexpressed in breast cancer and other solid tumors, such as Prostate Cancer and Non-Small Cell Lung Cancer (NSCLC), positioning ATNM-400 as a potential pan-tumor radiotherapy solution.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/ATNM">Actinium’s stock</a> traded over 3% higher in Friday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘neutral’ territory amid ‘normal’ message volume levels.&nbsp;<h2 class="st-heading-2">Effectiveness Against Resistant Cancer Types</h2>ATNM-400 displayed potent cytotoxic effects in models resistant to standard-of-care treatments, including trastuzumab-resistant BT474-Clone5 and tamoxifen-resistant MCF7-Tam1 cells. Combining ATNM-400 with conventional therapies like trastuzumab or tamoxifen enhanced tumor regression in preclinical models."Patients whose tumors progress after endocrine therapy or HER2-targeted therapies face limited and often toxic treatment options. The data presented at SABCS show that ATNM-400 generates potent, targeted DNA damage even in highly resistant breast cancer models, while maintaining a favorable tolerability profile,” said&nbsp;Aditya Bardia, Program Director, Breast Medical Oncology at Geffen School of Medicine, University of California, Los Angeles.Researchers observed that ATNM-400 induced irreversible DNA damage, marked by elevated phosphorylation of H2AX (pH2AX) and AKT (pAKT), consistent with alpha-particle–driven double-strand DNA breaks.&nbsp;ATNM stock has gained over 17% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-weighs-boosting-h200-ai-chip-production-report/cLICS1gREF8">Nvidia Weighs Boosting H200 AI Chip Production: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Actinium Pharmaceuticals, Inc. logo is displayed on the screen of a tablet. 

Why Is Actinium Pharmaceuticals Stock Rising Today? 

The Actinium-225 (Ac-225) antibody radioconjugate demonstrated strong anti-tumor activity across multiple breast cancer models.

Equity

The Actinium-225 (Ac-225) antibody radioconjugate demonstrated strong anti-tumor activity across multiple breast cancer models.


Are Medical Stocks Lagging  Alpha Cognition Inc. (ACOG) This Year?

Here is how Alpha Cognition Inc. (ACOG) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.

Is Alpha Cognition Inc. (ACOG) Stock Outpacing Its Medical Peers This Year?

Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year?

Here is how Armata Pharmaceuticals, Inc. (ARMP) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.

Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?

Here is how Actinium Pharmaceuticals (ATNM) and Avadel (AVDL) have performed compared to their sector so far this year.

Regencell Bioscience Holdings Ltd (3,500% Jump in Message Volume)Hong Kong-based Regencell focuses on traditional Chinese medicine for neurocognitive disorders, particularly ADHD and autism. Reports suggest its recent rally was fueled by insider buying, with insiders owning 81% of the company.&nbsp;However, a Stocktwits&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rgc-stock-more-than-triples-this-year/ch7KEpeRbcl">poll</a> indicates retail traders remain skeptical, with some flagging it as a potential pump-and-dump risk.&nbsp;The stock has surged 1,054% this year.GlucoTrack Inc. (2,800% Jump in Message Volume)GlucoTrack develops non-invasive glucose monitoring devices. It announced that safety and performance data from its first-in-human trial of a long-term continuous blood glucose monitoring (CBGM) system will be presented at the 2025 ATTD conference.&nbsp;CEO Paul V. Goode highlighted its potential for real-time glucose monitoring without on-body wearables, calling it a transformative step in diabetes management.&nbsp;GlucoTrack stock is down over 96% year-to-date (YTD).TC Biopharm (Holdings) Plc (1,300% Jump in Message Volume)TC Biopharm&nbsp;<a href="https://stocktwits.com/symbol/TCBP">received</a> a Nasdaq delisting notice due to its share price falling below $1. Trading will be suspended on Monday, with its American depository shares expected to move to OTC Markets.&nbsp;The company is also shifting to a contract development and manufacturing organization (CDMO) model, cutting about 50% of its workforce to reduce operational burn by 55%. This is projected to save $2.1 million in 2025 and $4.2 million annually.&nbsp;The stock is down over 95% YTD.AbbVie Inc. (700% Jump in Message Volume)Erste Group upgraded AbbVie to ‘Buy’ from ‘Hold’, according to The Fly, citing strong sales growth projections through 2029, supported by upcoming product launches. The research firm expects earnings per share (EPS) to rise significantly in 2025, ranging from $12.12 to $12.32.&nbsp;AbbVie recently agreed to acquire a next-gen obesity drug from Denmark-based Gubra A/S for up to $2.2 billion, boosting sentiment.&nbsp;The stock is up over 17.5% YTD.Actinium Pharmaceuticals Inc. (600% Jump in Message Volume)Actinium is launching trials for its drug Actimab-A in combination with Merck’s Keytruda and Bristol Myers Squibb’s Opdivo to treat solid tumors. The trials will include head-to-head studies comparing Actimab-A combinations to standalone treatments.&nbsp;The company also entered a research agreement with Memorial Sloan Kettering to expand Actimab-A’s applications.&nbsp;Actinium stock is up over 22% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week

Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.

Current Price	$1.10
Prev Close	$0.9804
Open	$1.04
Dividend Yield	0.00%
50-Day Moving Average	$1.14
Beta	2.03
Avg. Volume	123,396.05
PE Ratio	-0.90

52-Week High	$1.95
52-Week Low	$0.9519
Market Capitalization	$30.76M
EPS (Annual)	-$1.09
Price to Book	3.90
Revenue Per Employee	$3,600.00

ATNM
Actinium Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ATNM News

ATNMActinium Pharmaceuticals Inc